An open label, randomized, phase III trial, evaluating efficacy of Atezolizumab in addition to one year BCG (Bacillus CaLmette-Guerin) bladder instillation in BCG-naive patients with high-risk non-muscle invasive Bladder cANcer
Phase of Trial: Phase III
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs Atezolizumab (Primary) ; BCG
- Indications Bladder cancer; Carcinoma; Urogenital cancer
- Focus Therapeutic Use
- Acronyms ALBAN
- 04 Jun 2019 Trial design presented at the 55th Annual Meeting of the American Society of Clinical Oncology.
- 01 Apr 2019 Status changed from not yet recruiting to recruiting.
- 08 Nov 2018 New trial record